Cargando…

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation

SIMPLE SUMMARY: Bendamustine is a chemotherapeutic agent used to treat a variety of cancers. It has recently been used in the context of allogeneic hematopoietic cell transplantation (HCT), a treatment mostly used to treat blood cancers. Given before or after transplantation of donor blood or bone m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stokes, Jessica, Molina, Megan S., Hoffman, Emely A., Simpson, Richard J., Katsanis, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038415/ https://www.ncbi.nlm.nih.gov/pubmed/33916711 http://dx.doi.org/10.3390/cancers13071702

Ejemplares similares

Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia
por: Stokes, Jessica, et al.
Publicado: (2020)

Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3
por: Molina, Megan S., et al.
Publicado: (2020)

Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death
por: Molina, Megan S., et al.
Publicado: (2021)

Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
por: Molina, Megan S., et al.
Publicado: (2022)

Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation
por: Stokes, Jessica, et al.
Publicado: (2022)

Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

Editorial: Advances in Pediatric Hematopoietic Cell Therapies and Transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2022)

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease
por: Gilman, Kristy E., et al.
Publicado: (2023)

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
por: Greenbaum, Adam M., et al.
Publicado: (2018)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?
por: Pariury, Holly, et al.
Publicado: (2021)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement
por: Sullivan, Keith M., et al.
Publicado: (2016)

Bendamustine: A review of pharmacology, clinical use and immunological effects
por: Lalic, Hrvoje, et al.
Publicado: (2022)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Bendamustine and pneumocystis pneumonia: A systematic review
por: Hakamifard, Atousa, et al.
Publicado: (2022)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
por: Yalnız, Fevzi Fırat, et al.
Publicado: (2017)

Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
por: Pinczés, László Imre, et al.
Publicado: (2020)

Immunological reactions induced by bendamustine
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine
por: Beeharry, Neil, et al.
Publicado: (2012)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases
por: Naumchik, Brianna M., et al.
Publicado: (2020)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

The immunological case for staying active during the COVID-19 pandemic
por: Simpson, Richard J., et al.
Publicado: (2020)

Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
por: Ramos, Jéssica Fernandes, et al.
Publicado: (2013)

Hematopoietic stem cell transplantation
por: Hatzimichael, Eleftheria, et al.
Publicado: (2010)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Bendamustine Associated with Irreversible Ascending Paralysis
por: Alhafez, Ashraf, et al.
Publicado: (2013)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
por: Shabbir-Moosajee, Munira, et al.
Publicado: (2019)

Expansion of hematopoietic stem cells for transplantation: current perspectives
por: Schuster, Jessica A, et al.
Publicado: (2012)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

The immunomodulatory role of carbon monoxide during transplantation
por: Amano, Mariane Tami, et al.
Publicado: (2013)

Endothelial Dysfunction in Hematopoietic Cell Transplantation
por: Palomo, Marta, et al.
Publicado: (2019)

Effect of rehabilitation in patients undergoing hematopoietic stem cell transplantation
por: Takekiyo, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_59rfcjdibqqa54svq68e31qnqk